Gain Therapeutics Stock Today
| GANX Stock | USD 2.47 0.09 3.78% |
PerformanceGood
| Odds Of DistressLow
|
Gain Therapeutics is trading at 2.47 as of the 20th of March 2025; that is 3.78 percent increase since the beginning of the trading day. The stock's open price was 2.38. Gain Therapeutics has less than a 16 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of March 2021 | Category Healthcare | Classification Health Care |
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. The company was founded in 2017 and is based in Bethesda, Maryland. Gain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 26.53 M outstanding shares of which 462.16 K shares are currently shorted by private and institutional investors with about 1.44 trading days to cover. More on Gain Therapeutics
Moving together with Gain Stock
Moving against Gain Stock
Gain Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | LLM IUR | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGain Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gain Therapeutics' financial leverage. It provides some insight into what part of Gain Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain Therapeutics (GANX) is traded on NASDAQ Exchange in USA. It is located in 4800 Montgomery Lane, Bethesda, MD, United States, 20814 and employs 29 people. Gain Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.47 M. Gain Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.53 M outstanding shares of which 462.16 K shares are currently shorted by private and institutional investors with about 1.44 trading days to cover.
Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04.
Check Gain Therapeutics Probability Of Bankruptcy
Ownership AllocationGain Therapeutics has a total of 26.53 Million outstanding shares. Gain Therapeutics retains 5.0 (percent) of its outstanding shares held by insiders and 7.64 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Gain Ownership Details
Gain Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Springbok Capital Management, Llc | 2024-12-31 | 35.8 K | |
| Ubs Group Ag | 2024-12-31 | 35.2 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 30 K | |
| Royal Bank Of Canada | 2024-12-31 | 17.5 K | |
| Benedict Financial Advisors, Inc. | 2024-12-31 | 16 K | |
| Sandhill Capital Partners Llc | 2024-12-31 | 15.4 K | |
| Sprott Inc. | 2024-12-31 | 14 K | |
| Citadel Advisors Llc | 2024-12-31 | 11.6 K | |
| Creekmur Asset Management Llc | 2024-12-31 | 4.4 K | |
| Geode Capital Management, Llc | 2024-12-31 | 267.4 K | |
| Vanguard Group Inc | 2024-12-31 | 177.1 K |
Gain Therapeutics Historical Income Statement
Gain Stock Against Markets
Gain Therapeutics Corporate Management
| Gianluca Fuggetta | Principal Reporting | Profile | |
| Xavier Barril | Chief Officer | Profile | |
| Joanne Taylor | Senior Research | Profile | |
| Terenzio PharmD | Senior Operations | Profile | |
| Salvatore Calabrese | CFO Sec | Profile |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.